France · Biotechnology startup
France · Amolyt Pharma
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.
Funding reportedLast round: Series C
What company datasets say Amolyt Pharma raised
Funding, as reported
Reported in all311.3Min the source's currency
Rounds9
Last roundSeries C
Last round dateJan 2023
Investors listed24
On a portfolio page
Investors who name them
Each firm lists Amolyt Pharma on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in France
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Amolyt Pharma in front of investors. Or tell us what we have wrong.